Efficacy and safety of icotrokinra, a novel targeted oral peptide (IL-23R-inhibitor), in adolescents with moderate-to-severe plaque psoriasis: subgroup analyses from a phase‑3, randomized, double-blind, placebo-controlled study (iCONIC-LEAD)
In this medfyle
Adolescent subset data from ICONIC-LEAD show high rates of skin clearance. This is the first pivotal Phase 3 study evaluating a systemic advanced therapy for moderate-to-severe plaque psoriasis in both adults and adolescents at the same time.
About this Medfyle
©2025 Infomedica-Medfyle. All rights reserved.
Source: Efficacy and safety of icotrokinra, a novel targeted oral peptide (IL-23R-inhibitor), in adolescents with moderate-to-severe plaque psoriasis: subgroup analyses from a phase‑3, randomized, double-blind, placebo-controlled study (iCONIC-LEAD). Eichenfield L, et al. Presented at EADV 2025; abstract 6621; FC02.
The information and data provided is for information purposes only. The author(s) of the original presentation had no involvement in the creation of this content.
